NCT05756764

Anti-obesity Pharmacotherapy and Inflammation

Pilot Study of the Effect of Weight Loss by Pharmacotherapy on Chronic Pro-tumor Inflammatory Cells

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 30 (estimated)
• Sponsor: Louisiana State University Health Sciences Center in New Orleans · Academic / Other
• Sex: All
• Age: 35 Years – 60 Years
• Healthy volunteers: —

Summary

This study evaluates the relationship between weight loss, circulating inflammatory markers and lipids from 24 patients before and after 6 months of pharmacotherapy as a standard of care for anti-obesity treatment

Detailed description

This study aims to determine if weight loss by pharmacotherapy with liraglutide, semaglutide, or phentermine-topiramate promotes the reduction of pro-tumoral inflammatory cells Myeloid-derived suppressor cells (MDSC), simultaneously to the improvement of lipid profile (LDL-Cholesterol, HDL-Cholesterol, triglycerides, and free fatty acids) and concentration in the blood. Liraglutide, semaglutide, and phentermine-topiramate are FDA-approved medications to treat obesity and obesity-associated comorbidities. Twenty-four patients undergoing standard of care for anti-obesity treatment at VA Medical Center, and Tulane Center for Clinical Research (TCCR) will be recruited before initiation of pharmacotherapy as part of their standard of care and followed up to 6 months to compare the primary study variables.

Conditions

• Obesity

Interventions

Type	Name	Description
DRUG	Semaglutide	Medication for weight loss
DRUG	Phentermine-Topiramate combination	Medication for weight loss
DRUG	Phentermine	Medication for weight loss
DRUG	Tirzepatide	Medication for weight loss
DRUG	Topiramate	Medication for weight loss
DRUG	Diethylpropion	Medication for weight loss
DRUG	Naltrexone/Bupropion	Medication for weight loss
DRUG	Liraglutide	Medication for weight loss

Timeline

• Start date: 2023-06-01
• Primary completion: 2026-01-30
• Completion: 2026-02-20
• First posted: 2023-03-06
• Last updated: 2025-09-09

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study